News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dyax Corp. (DYAX) Licenses Antibody Phage Display Libraries to Cambridge Antibody Technology Group PLC  (CATG)


8/2/2007 11:50:12 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that they have licensed their antibody phage display libraries to Cambridge Antibody Technology (CAT), a wholly-owned subsidiary of AstraZeneca, for the discovery of therapeutic antibodies. CAT will receive sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’s technology. The agreement allows CAT the ability to commercialize up to 20 royalty bearing therapeutic antibody products. Financial terms of the agreement are not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES